0001628280-26-034084
SEC filingOpus Genetics reported a $2.2M revenue decline year-over-year, reflecting reduced PS research and development services, while net loss widened significantly to $65.5M due to increased operating expenses and non-cash warrant liability adjustments.
Revenue for Q1 FY2026 totaled $2.2M, a 50.6% decrease from $4.4M in Q1 FY2025. As stated in the Full Filing Text, this decline was due to a reduction in PS research and development services under license and collaborations arrangements. The absence of new partnership milestones or service ramp-ups during the quarter contributed to the lower revenue base.
Operating income was -$14.4M, a 44.7% deterioration from -$9.9M in the prior-year quarter. This reflects continued investment in clinical development and infrastructure for inherited retinal disease (IRD) programs. With revenue at $2.2M, the operating margin was -665.9%, underscoring the early-stage nature of the business model where R&D spend substantially exceeds near-term commercial revenue.
Net income was -$65.5M, compared to -$8.2M in Q1 FY2025 — a 699.8% decline. Diluted EPS was -$0.75, versus -$0.24 in the prior year. The magnitude of the net loss increase is largely attributable to non-cash changes in the fair value of warrant liabilities, which are sensitive to stock price, volatility, and term assumptions under ASC 815. These adjustments are required under GAAP but do not represent cash outflows or operational performance shifts.
Net cash used in operating activities was -$12.7M, up from -$9.0M in Q1 FY2025. Per the Full Filing Text, this change stemmed primarily from movements in operating assets and liabilities: a net decrease in accounts payable and accrued expenses, an increase in prepaid expenses and other assets, partially offset by a decrease in accounts receivable and contract assets. No unregistered sales of equity securities occurred during the quarter, per Item 2 disclosures.
Management states that the Company’s ability to transition to profitability depends on achieving product sales sufficient to support its cost structure. While the Full Filing Text references a cash and cash equivalents balance as of March 31, 2026, the specific figure is not included in the authoritative XBRL packet and therefore omitted here to ensure factual safety. Subsequent events, including financing activities, are disclosed separately in Note 14 and related sections.